title: Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
abstract: BACKGROUND
  Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc.
  
  
  METHODS
  Two large phase 3 studies of maraviroc enrolled HIV-infected treatment-experienced patients and followed them up for 5 or more years. Survival and selected clinical end points were identified and assessed.
  
  
  RESULTS
  A total of 938 enrolled patients received maraviroc-containing regimens. Rates of death and selected clinical events (eg, hepatic failure, malignancy, and myocardial infarction) were low during follow-up.
  
  
  CONCLUSIONS
  Maraviroc was generally safe in treatment-experienced participants for >5 years.
authors.affiliation: *Weill Cornell Medical College, New York, NY; †University Hospital of Cologne, Cologne, Germany; ‡Pfizer, Inc, Groton, CT; §David Geffen School of Medicine at UCLA, Los Angeles, CA; ‖Chelsea and Westminster Hospital, London, United Kingdom; ¶ViiV Healthcare, Research Triangle Park, NC; #Pfizer, Inc, New York, NY; and **Bristol-Myers Squibb, Wallingford, CT. 1Deceased.
authors.forename: Roy M
authors.initials: RM
authors.lastname: Gulick
authors.forename: Gerd
authors.initials: G
authors.lastname: Fatkenheuer
authors.forename: Robert
authors.initials: R
authors.lastname: Burnside
authors.forename: W David
authors.initials: WD
authors.lastname: Hardy
authors.forename: Mark R
authors.initials: MR
authors.lastname: Nelson
authors.forename: James
authors.initials: J
authors.lastname: Goodrich
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Mukwaya
authors.forename: Simon
authors.initials: S
authors.lastname: Portsmouth
authors.forename: Jayvant R
authors.initials: JR
authors.lastname: Heera
mesh_terms: D000328:Adult; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000009:adverse effects* / Q000627:therapeutic use; D004311:Double-Blind Method; D023581:HIV Fusion Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D000077592:Maraviroc; D016019:Survival Analysis; D013997:Time Factors; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc